secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001104659-24-046970
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio launches OviTex IHR for inguinal hernia repair in U.S.
---------------------------------------------------------------

- OviTex IHR targets over 665,000 annual U.S. inguinal hernia procedures; three configurations available.
- Builds on OviTex portfolio with >45,000 implantations and 8 years clinical experience.
- Study on 259 patients using ReBAR technique showed low 1.2% recurrence rate at 1.5-year follow-up.
- Designed for laparoscopic and robotic-assisted repair; aims to address shortcomings of permanent synthetic mesh.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924046970/0001104659-24-046970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465924046970/tm2411582d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-046970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer